<DOC>
	<DOC>NCT00631358</DOC>
	<brief_summary>The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.</brief_summary>
	<brief_title>Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention</brief_title>
	<detailed_description />
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria of Sjorgren's Population: 17 years or older LogMar visual acuity of 0.6 or better Ocular inflammation associated with Sjogren's Syndrome Has had an adverse reaction to either topical of systemic steroids in the past Has diabetes (type 1 or 2) Has glaucoma or evidence of ocular hypertension in either eye or treatment of either within six months of Visit 1 Has worn contact lenses within one week prior to Visit 1 Has received ocular prescription therapy in the last 30 days Has active ocular infections or inflammation not associated with Sjogren's Syndrome. Has any finding in the vitreous, macula, retina or choroid that show signs of inflammation and/or any structural change that in the opinion of the investigator is considered abnormal or unstable for that participant</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Ocular inflammation</keyword>
</DOC>